Logical Therapeutics, Inc. In-Licenses Novel Anti-Inflammatory Drug

PITTSBURGH, Sept. 5 /PRNewswire/ -- Logical Therapeutics, Inc. (Pittsburgh, PA) has entered into a licensing and collaboration agreement with Medinox, Inc. (Carlsbad, CA) for a novel non-steroidal anti-inflammatory agent (NSAID), to be known as LT-NS001.

LT-NS001 is a patented, orally active anti-inflammatory agent that has been shown to be as effective for treating pain and inflammation as the widely used NSAID, naproxen, in animal models. Furthermore, in animal models of NSAID-induced damage to the mucosal lining of the gastrointestinal tract, LT- NS001 was significantly less injurious than naproxen. LT-NS001 was evaluated in 47 subjects in a Phase I clinical trial. No serious adverse events were reported and no subjects were withdrawn from the study.

Logical Therapeutics intends to develop LT-NS001 for the treatment of mild to moderate inflammatory conditions, such as osteoarthritis (degenerative joint disease) and low back pain syndrome.

Under the terms of the deal, Logical Therapeutics has an exclusive license to develop and market LT-NS001 in North America, Europe and Australia. In return, Medinox will receive an upfront payment, and is eligible to receive future payments upon achievement of certain development and regulatory milestones, as well as royalties on sales.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Pittsburgh, Pennsylvania. The company is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. For more information on Logical Therapeutics, visit the company's website at http://www.logicaltherapeutics.com or by email at info@logicaltherapeutics.com

About Medinox, Inc.

Medinox is a leader in nitric-oxide ("NO") therapeutics and is developing a broad technology platform to address a wide variety of unmet medical needs including septic shock, acute respiratory distress syndrome (including SARS) and hemorrhagic shock. In addition to its NO technology, Medinox is also developing MX-1520, a unique therapeutic for sickle cell anemia. For information about Medinox and its products, please visit the Company's website at http://www.medinox.com, or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc., at (760) 603-8989, or by email at cslai@medinox.com

Source: Logical Therapeutics, Inc.

Back to news